Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Explore how neutrophils shape the immune response in health and disease. This poster highlights neutrophil pathogen defense mechanisms, including phagocytosis, degranulation, and NETosis, as well as neutrophil roles in inflammation and NET-associated pathologies.
DOWNLOAD NOWNorfloxacin is a fluoroquinolone antibiotic that inhibits the growth of Gram-positive and Gram-negative bacteria (MICs = 4 and 1 μg/ml for S. aureus and P. aeruginosa, respectively).1 It also inhibits the growth S. pseudintermedius, S. aureus, E. coli, Pasturella, and S. canis isolates from dogs (mean MIC50s = 0.25, 1, 0.03, 1, and 1 μg/ml, respectively).2 Topical administration of norfloxacin (0.1% v/v) reduces corneal ulcer size in a rabbit model of P. aeruginosa corneal infection. It also prevents encrusted cystitis in bladder and increases survival in a rat model of Corynebacterium group D2 infection when administered at a dose of 80 mg/kg per day.3 Formulations containing norfloxacin have been used to treat urinary tract and gynecological infections.
WARNING This product is not for human or veterinary use.
1. Norfloxacin and silver norfloxacin in the treatment of Pseudomonas corneal ulcer in the rabbit. Trans. Am. Opthalmol. Soc. 82, 75-91 (1984).
2. The in vitro activity of 15 antimicrobial agents against bacterial isolates from dogs. J. Vet. Med. Sci. 74(8), 1091-1094 (2012).
3. Treatment of encrusted cystitis caused by Corynebacterium group D2 with norfloxacin, ciprofloxacin, and teicoplanin in an experimental model in rats. Antimicrob. Agents Chemother. 35(12), 2587-2590 (1991).